Skip to main content
TipRanks
Go Ultimate75% OFF

VSee Health (VSEE) AI Stock Analysis

234 Followers
VSEE

VSee Health

(Other OTC:VSEE)

Select Model
Rating:39Underperform
Price Target:$0.31â–¼(-5.45% Downside)
Action:reiterated
Date:11/14/26

Weak financial performance from sustained losses and cash burn is the dominant factor, compounded by negative valuation and bearish technical indicators; corporate governance approvals provide only minor support.

Positive Factors
Manageable LeverageThe latest balance sheet shows relatively manageable leverage, giving VSee Health more financial flexibility than a highly indebted business. Although losses remain significant, the modest debt burden may reduce immediate interest and refinancing pressure while management works to improve operating performance.
Negative Factors
Revenue ContractionRevenue contraction weakens the scale foundation needed to support VSee Health’s telehealth infrastructure and service model. Reversing the decline is important because a smaller revenue base makes fixed operating costs harder to absorb and reduces the resources available for product development and expansion.

VSee Health (VSEE) vs. SPDR S&P 500 ETF (SPY)

-100%-75%-50%-25%0%25%VSEE-99.34%SPY+14.55%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
$322.43K
Dividend Yield
―
Average Volume (3M)
10.35K
Price to Earnings (P/E)
-0.0
Beta (1Y)
0.90
Revenue Growth
-9.31%
EPS Growth
89.42%
Country
US
Employees
209
Sector
Healthcare
Sector Strength
51
Industry
Medical - Healthcare Information Services

VSee Health Business Overview & Revenue Model

Company Description

VSee Health, Inc. specializes in delivering virtual healthcare solutions. Their flagship offering, iDoc Telehealth, is specifically designed to manage and coordinate comprehensive care for severely ill individuals within various critical care environ...

VSee Health Financial Statement Overview

Summary

Persistent net losses, sharply lower gross margins, negative cash flows exceeding $5 million TTM, and prior balance sheet volatility result in fragile financial health.

Income Statement

22Negative

Balance Sheet

38Negative

Cash Flow

12Very Negative
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue12.63M14.62M10.42M5.77M6.38M7.34M
Gross Profit4.76M7.36M7.18M3.83M4.84M5.92M
EBITDA-9.03M-9.18M-3.30M-1.79M0386.34K
Net Income-13.82M-14.71M-57.70M-3.76M-836.21K475.90K
Balance Sheet
Total Assets16.73M22.41M19.99M805.79K2.61M117.94M
Cash, Cash Equivalents and Short-Term Investments454.15K5.27M326.12K118.73K230.66K760.01K
Total Debt1.88M2.44M9.55M543.00K517.13K0
Total Liabilities9.14M16.96M20.01M5.11M2.61M4.55M
Stockholders Equity7.59M5.45M-18.49K-3.97M360.72K113.39M
Cash Flow
Free Cash Flow-6.32M-3.48M-5.84M-636.93K-1.45M-600.11K
Operating Cash Flow-6.31M-3.45M-5.79M-632.60K-1.45M-600.11K
Investing Cash Flow-143.21K-29.93K-26.14K-4,335110.12M-116.73M
Financing Cash Flow6.83M8.42M6.02M525.00K-109.32M118.09M

VSee Health Technical Analysis

Technical Analysis SentimentNegative
Last Price0.33

Price Trends

50DMA1.56Negative
100DMA3.48Negative
200DMA11.30Negative

Market Momentum

MACD-0.33Positive
RSI20.89Positive
STOCH13.34Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For VSEE, the sentiment is Negative. The current price of 0.33 is below the 20-day moving average (MA) of 1.47, below the 50-day MA of 1.56, and below the 200-day MA of 11.30, indicating a bearish trend. The MACD of -0.33 indicates Positive momentum. The RSI at 20.89 is Positive, neither overbought nor oversold. The STOCH value of 13.34 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for VSEE.

VSee Health Risk Analysis

VSee Health disclosed 62 risk factors in its most recent earnings report. VSee Health reported the most risks in the "Finance & Corporate" category.

Higher RiskSector Avg.Lower RiskFinance & CorporateTech & InnovationLegal & RegulatoryProductionAbility to SellMacro & Political
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy

Latest Risks Added

3 New Risks
1.The Company is currently subject to a delisting determination by the staff of Nasdaq, and trading of its common stock was halted on August 6, 2026. The Company expects that after its common stock is delisted from Nasdaq, its common stock will begin trading on the OTC Pink Limited Market, which may affect the market price and liquidity of the shares and could limit the Company's ability to raise additional capital.Q2, 2026
2.Investors could experience a reduction in share price for our Common Stock they own, or dilution resulting from the exercise of warrants into Common Stock or the conversion of preferred stock into Common Stock, or the vesting and settlement of equity grants to employees, directors and consultants.Q4, 2025
3.If our shares become subject to the penny stock rules, it would become more difficult to trade our shares.Q4, 2025

VSee Health Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

VSEE against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
AMWLAMWL57Neutral$211.98M-3.55-25.49%―-20.30%52.30%
TDOCTDOC56Neutral$1.63B-10.07-11.63%―-2.38%32.73%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
ZCMDZCMD43Neutral$4.33M-0.00-53.52%―-49.58%-31.56%
VSEEVSEE39Underperform$554.18K-0.01-400.87%―-9.31%89.42%

* Healthcare Sector Average

Performance Comparison

-100%0%100%200%VSEETDOCZCMDAMWLONMDEUDADec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
VSEE and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
VSEEVsee Health, Inc.0.33-55.75-99.41%
TDOCTeladoc Inc.8.802.0530.37%
ZCMDZhongchao Inc0.90-900.83-99.90%
AMWLAmerican Well Corporation11.747.78196.46%
ONMDOnemednet Corp5.34-8.16-60.44%
EUDAEuda Health Holdings Limited15.55-39.85-71.93%

VSee Health Corporate Events

Regulatory Filings and ComplianceStock Split

VSee Health Announces 1-for-80 Reverse Stock Split

Neutral
Sep 23, 2026

On September 22, 2026, VSee Health, Inc. filed a Certificate of Amendment to implement a 1-for-80 reverse stock split of its common stock, effective at 5:00 p.m. Eastern on September 23, 2026, with split-adjusted trading to begin on September 24, 202...

Business Operations and StrategyPrivate Placements and Financing

VSee Health Pursues Private Equity Financing Strategy

Neutral
Sep 9, 2026

VSee Health disclosed that it is issuing Commitment Fee Shares and additional common stock under a Strata Agreement through a private offering structure rather than a public securities issuance. The company is relying on exemptions under Section 4(a)...

Executive/Board ChangesShareholder MeetingsStock Split

VSee Health Shareholders Approve Reverse Split Flexibility

Positive
Aug 26, 2026

On August 25, 2026, VSee Health, Inc. held its annual meeting of stockholders for the fiscal year ended December 31, 2026, with a quorum representing 50.65% of voting shares present in person or by proxy. Shareholders elected directors Kevin Lowdermi...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 13, 2026